High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits and implications for clinical practice.
Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.